The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy
Glioblastoma (GBM) is known to be the most common and lethal primary malignant brain tumor. Therapies against this neoplasia have a high percentage of failure, associated with the survival of self-renewing glioblastoma stem cells (GSCs), which repopulate treated tumors. In addition, despite new radi...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/8/3863 |
id |
doaj-31a43839851046ee939286f7e1e96f9b |
---|---|
record_format |
Article |
spelling |
doaj-31a43839851046ee939286f7e1e96f9b2021-04-08T23:04:53ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-04-01223863386310.3390/ijms22083863The Importance of Tumor Stem Cells in Glioblastoma Resistance to TherapyVincenzo Mattei0Francesca Santilli1Stefano Martellucci2Simona Delle Monache3Jessica Fabrizi4Alessandro Colapietro5Adriano Angelucci6Claudio Festuccia7Biomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, ItalyBiomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, ItalyBiomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, ItalyDepartment of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, ItalyBiomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, ItalyDepartment of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, ItalyDepartment of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, ItalyDepartment of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, ItalyGlioblastoma (GBM) is known to be the most common and lethal primary malignant brain tumor. Therapies against this neoplasia have a high percentage of failure, associated with the survival of self-renewing glioblastoma stem cells (GSCs), which repopulate treated tumors. In addition, despite new radical surgery protocols and the introduction of new anticancer drugs, protocols for treatment, and technical advances in radiotherapy, no significant improvement in the survival rate for GBMs has been realized. Thus, novel antitarget therapies could be used in conjunction with standard radiochemotherapy approaches. Targeted therapy, indeed, may address specific targets that play an essential role in the proliferation, survival, and invasiveness of GBM cells, including numerous molecules involved in signal transduction pathways. Significant cellular heterogeneity and the hierarchy with GSCs showing a therapy-resistant phenotype could explain tumor recurrence and local invasiveness and, therefore, may be a target for new therapies. Therefore, the forced differentiation of GSCs may be a promising new approach in GBM treatment. This article provides an updated review of the current standard and experimental therapies for GBM, as well as an overview of the molecular characteristics of GSCs, the mechanisms that activate resistance to current treatments, and a new antitumor strategy for treating GSCs for use as therapy.https://www.mdpi.com/1422-0067/22/8/3863glioblastomaglioblastoma stem cellscancer stem cellsglioblastoma therapy resistanceglioblastoma stem cells and therapy resistancenew drugs in the treatment of glioblastoma stem cells |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vincenzo Mattei Francesca Santilli Stefano Martellucci Simona Delle Monache Jessica Fabrizi Alessandro Colapietro Adriano Angelucci Claudio Festuccia |
spellingShingle |
Vincenzo Mattei Francesca Santilli Stefano Martellucci Simona Delle Monache Jessica Fabrizi Alessandro Colapietro Adriano Angelucci Claudio Festuccia The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy International Journal of Molecular Sciences glioblastoma glioblastoma stem cells cancer stem cells glioblastoma therapy resistance glioblastoma stem cells and therapy resistance new drugs in the treatment of glioblastoma stem cells |
author_facet |
Vincenzo Mattei Francesca Santilli Stefano Martellucci Simona Delle Monache Jessica Fabrizi Alessandro Colapietro Adriano Angelucci Claudio Festuccia |
author_sort |
Vincenzo Mattei |
title |
The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy |
title_short |
The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy |
title_full |
The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy |
title_fullStr |
The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy |
title_full_unstemmed |
The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy |
title_sort |
importance of tumor stem cells in glioblastoma resistance to therapy |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-04-01 |
description |
Glioblastoma (GBM) is known to be the most common and lethal primary malignant brain tumor. Therapies against this neoplasia have a high percentage of failure, associated with the survival of self-renewing glioblastoma stem cells (GSCs), which repopulate treated tumors. In addition, despite new radical surgery protocols and the introduction of new anticancer drugs, protocols for treatment, and technical advances in radiotherapy, no significant improvement in the survival rate for GBMs has been realized. Thus, novel antitarget therapies could be used in conjunction with standard radiochemotherapy approaches. Targeted therapy, indeed, may address specific targets that play an essential role in the proliferation, survival, and invasiveness of GBM cells, including numerous molecules involved in signal transduction pathways. Significant cellular heterogeneity and the hierarchy with GSCs showing a therapy-resistant phenotype could explain tumor recurrence and local invasiveness and, therefore, may be a target for new therapies. Therefore, the forced differentiation of GSCs may be a promising new approach in GBM treatment. This article provides an updated review of the current standard and experimental therapies for GBM, as well as an overview of the molecular characteristics of GSCs, the mechanisms that activate resistance to current treatments, and a new antitumor strategy for treating GSCs for use as therapy. |
topic |
glioblastoma glioblastoma stem cells cancer stem cells glioblastoma therapy resistance glioblastoma stem cells and therapy resistance new drugs in the treatment of glioblastoma stem cells |
url |
https://www.mdpi.com/1422-0067/22/8/3863 |
work_keys_str_mv |
AT vincenzomattei theimportanceoftumorstemcellsinglioblastomaresistancetotherapy AT francescasantilli theimportanceoftumorstemcellsinglioblastomaresistancetotherapy AT stefanomartellucci theimportanceoftumorstemcellsinglioblastomaresistancetotherapy AT simonadellemonache theimportanceoftumorstemcellsinglioblastomaresistancetotherapy AT jessicafabrizi theimportanceoftumorstemcellsinglioblastomaresistancetotherapy AT alessandrocolapietro theimportanceoftumorstemcellsinglioblastomaresistancetotherapy AT adrianoangelucci theimportanceoftumorstemcellsinglioblastomaresistancetotherapy AT claudiofestuccia theimportanceoftumorstemcellsinglioblastomaresistancetotherapy AT vincenzomattei importanceoftumorstemcellsinglioblastomaresistancetotherapy AT francescasantilli importanceoftumorstemcellsinglioblastomaresistancetotherapy AT stefanomartellucci importanceoftumorstemcellsinglioblastomaresistancetotherapy AT simonadellemonache importanceoftumorstemcellsinglioblastomaresistancetotherapy AT jessicafabrizi importanceoftumorstemcellsinglioblastomaresistancetotherapy AT alessandrocolapietro importanceoftumorstemcellsinglioblastomaresistancetotherapy AT adrianoangelucci importanceoftumorstemcellsinglioblastomaresistancetotherapy AT claudiofestuccia importanceoftumorstemcellsinglioblastomaresistancetotherapy |
_version_ |
1721533312063766528 |